title: Pramipexole reduces the prevalence of fatigue in patients with Parkinson's disease.
abstract: OBJECTIVE
  The aim of this multicenter cross-sectional study was to assess the relation between fatigue in a large number of Japanese patients with Parkinson's disease (PD) and drugs taken to treat PD.
  
  
  METHODS
  We used the 16-item Parkinson Fatigue Scale (PFS-16), which was designed to assess fatigue exclusively associated with PD. Multiple logistic regression analyses were used to assess the relation between antiparkinson drugs and fatigue in PD.
  
  
  RESULTS
  A total of 350 non-demented PD patients were enrolled. Fatigue (PFS score of ≥4) was revealed in 319 patients (91%). Pramipexole was administered to 24% of PD patients. Multiple logistic regression analysis revealed that the administration of Pramipexole was significantly related to low rates of fatigue in PD patients with Hoehn and Yahr stage <3 (p=0.011, odds ratio=5.23, 95% confidence interval; 1.47-18.63).
  
  
  CONCLUSIONS
  The reduced fatigue in PD patients was observed in taking Pramipexole.
authors.affiliation: Division of Neurology, Department of Medicine, Nihon University School of Medicine, Japan.
authors.forename: Akihiko
authors.initials: A
authors.lastname: Morita
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Okuma
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kamei
authors.forename: Fumihito
authors.initials: F
authors.lastname: Yoshii
authors.forename: Toshimasa
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Shiori
authors.initials: S
authors.lastname: Hashimoto
authors.forename: Hiroya
authors.initials: H
authors.lastname: Utsumi
authors.forename: Taku
authors.initials: T
authors.lastname: Hatano
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Hattori
authors.forename: Miyuki
authors.initials: M
authors.lastname: Matsumura
authors.forename: Kazushi
authors.initials: K
authors.lastname: Takahashi
authors.forename: Shigeru
authors.initials: S
authors.lastname: Nogawa
authors.forename: Yuka
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Miyamoto
authors.forename: Masayuki
authors.initials: M
authors.lastname: Miyamoto
authors.forename: Koichi
authors.initials: K
authors.lastname: Hirata
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D052160:Benzothiazoles / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D005221:Fatigue / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy*; D000077487:Pramipexole
chemical_list: D000978:Antiparkinson Agents; D052160:Benzothiazoles; D000077487:Pramipexole